The Scan by 2 Minute Medicine®: Viral menopause cocktail spreads without clinical evidence, maxxing trends raise body dysmorphia concerns, post-treatment opioid overdose risk remains high, Bundibugyo Ebola outbreak surpasses 5,000 cases, and coffee intake is linked to lower visceral fat

Viral menopause cocktail lacks evidence for treating vasomotor symptoms

A combination of fexofenadine (Allegra) and famotidine (Pepcid) has gained traction on social media as an over-the-counter approach to hot flashes, brain fog, sleep disruption, and other symptoms attributed to perimenopause. The viral menopause cocktail is appealing because both medications are inexpensive, familiar, and available without a prescription. Fexofenadine blocks histamine H1 receptors, while famotidine blocks histamine H2 receptors, creating a mechanistically plausible explanation that has helped the combination spread online. Plausibility, however, is not efficacy. No randomized clinical trial has established that the combination improves vasomotor symptoms, and neither medication is approved by the Food and Drug Administration (FDA) for menopause. Famotidine also reduces gastric acidity, and its prescribing information identifies clinically relevant drug interactions with medications whose absorption depends on gastric pH. The larger concern is what patients may be substituting the cocktail for. New or atypical flushing, palpitations, sleep disturbance, or other presumed menopausal symptoms may warrant evaluation for thyroid disease, medication effects, or other medical causes rather than empiric treatment based on a social media protocol. When menopause is the diagnosis, hormone therapy remains the most effective treatment for vasomotor symptoms in appropriately selected patients, particularly symptomatic women younger than 60 years or within 10 years of menopause onset who do not have contraindications. Patients who cannot or do not want to use hormones also have evidence-based nonhormonal options, including selected selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant, and other approaches. When a patient mentions Allegra and Pepcid for menopause, the most useful response is not simply to dismiss what she found online. Ask which symptoms prompted treatment, determine whether further evaluation is warranted, review medication interactions, and redirect the conversation toward therapies with established efficacy and a risk-benefit profile that can actually be discussed.

Maxxing trends range from sleep optimization to adolescent body image concerns

The suffix “-maxxing” has expanded from niche appearance communities into sleep, nutrition, exercise, fertility, and nearly every other corner of online health optimization. Some versions package familiar health advice under new language. Sleepmaxxing may involve a consistent sleep schedule, a dark room, less evening screen exposure, and other basic sleep hygiene practices. Problems emerge when optimization becomes rigid measurement and patients begin treating wearable-generated scores as clinical endpoints. Sleep medicine has described orthosomnia, in which patients become preoccupied with improving or perfecting wearable sleep data and may inadvertently reinforce sleep-related anxiety or poor sleep behaviors. Looksmaxxing raises a different set of concerns, particularly among adolescents and young men. The trend ranges from ordinary skincare, grooming, nutrition, and resistance training to mewing, extreme dieting, injectable peptides, repeated facial measurements, and attempts to manipulate facial structure. It has now been characterized in Pediatrics as an emerging pediatric concern because appearance-focused communities can normalize self-directed interventions whose efficacy and safety have not been established. Some practices move considerably beyond harmless experimentation. Clinicians caring for adolescents have described extreme dieting, unapproved peptides, stimulant misuse, anabolic steroid use, and attempts to physically alter facial features among the higher-risk behaviors circulating within looksmaxxing communities. The psychological context deserves at least as much attention as the specific technique. Body dysmorphic disorder has an estimated 2.4% prevalence in the United States adult population and can involve substantial distress and functional impairment. For clinicians, the practical value of learning terms such as looksmaxxing and mewing is not keeping up with internet slang. It is recognizing what the terminology may be signaling. Repetitive mirror checking, persistent facial measurements, restrictive eating, requests for unnecessary cosmetic procedures, social withdrawal, or significant distress over perceived defects should prompt assessment for body dysmorphic disorder and related psychiatric concerns. A teenager asking whether mewing works may need a short anatomy explanation. A teenager organizing daily life around achieving a mathematically “ideal” face requires a different clinical conversation.

Bundibugyo Ebola outbreak in Congo surpasses 5,000 confirmed cases

The Ebola outbreak in the Democratic Republic of the Congo (DRC) expanded dramatically through the summer and is now the largest outbreak of Ebola disease ever recorded in the country, irrespective of Ebola virus species. The epidemic is caused by Bundibugyo virus rather than the Ebola virus responsible for the major Zaire-species outbreaks, an important distinction because the available vaccine and species-specific therapeutics cannot automatically be assumed to provide clinically meaningful protection against Bundibugyo virus. As of August 26, the DRC had reported 5,794 confirmed cases and 2,786 deaths across 60 health zones in six provinces, corresponding to a 48.1% fatality rate. The outbreak is occurring in areas affected by limited health infrastructure, displacement, population movement, insecurity, and violence against health workers, all of which complicate case detection, contact tracing, isolation, and delivery of supportive care. Vaccination remains considerably more complicated than it was during previous Zaire ebolavirus outbreaks. Updated guidance published September 1 concludes that evidence remains insufficient to determine whether Ervebo provides clinically meaningful protection against Bundibugyo virus in humans and recommends use only within research protocols. For physicians in the United States, the immediate risk remains low. No outbreak-associated U.S. cases have been reported, and the likelihood of spread to the United States is considered very low. The practical issue is therefore recognition rather than expectation of widespread domestic disease. A patient with fever, gastrointestinal symptoms, unexplained bleeding, or another compatible syndrome should prompt a detailed travel and exposure history before routine diagnostic pathways proceed. Relevant exposure to an affected region should trigger prompt separation from other patients and early coordination with infection prevention and public health authorities. The geographic expansion of the outbreak makes that travel history increasingly important, even while the absolute risk to most patients seen in the United States remains very low.

Finnish cohort links coffee intake to leaner body composition

Coffee has accumulated a large observational literature around cardiometabolic health, but a recent Finnish analysis asked a more specific question: do habitual coffee drinkers differ in body composition and metabolic markers even when body mass index (BMI) appears similar? The cross-sectional study included 2,264 participants from the Northern Finland Birth Cohort 1966 at age 46 and combined self-reported coffee consumption with body composition measurements, circulating metabolites, cardiometabolic measurements, and sex hormone profiles. The distinction between BMI and more direct body composition measures was one of the more interesting findings. Higher coffee intake groups had lower body fat percentage, lower absolute fat mass, lower visceral fat, and greater skeletal muscle mass despite similar BMI across consumption groups. Higher coffee consumption was also inversely correlated with circulating branched-chain amino acids in both sexes, while men demonstrated a more favorable glucose-insulin profile and a distinct androgen-related hormonal pattern. These findings do not establish that coffee caused any of the differences. The analysis was cross-sectional, coffee intake was self-reported, and higher-consumption groups differed in characteristics such as education and smoking. The findings are nevertheless directionally consistent with a broader epidemiologic literature. A systematic review and dose-response meta-analysis of 28 prospective studies involving more than 1.1 million participants found an inverse association between coffee consumption and diabetes risk, with associations observed for both caffeinated and decaffeinated coffee. None of this makes coffee a body composition treatment or a reason to encourage escalating caffeine intake. For most healthy adults, approximately 400 milligrams of caffeine per day is an amount not generally associated with negative effects, although individual sensitivity varies and pregnancy, medications, and certain medical conditions change the discussion. The practical takeaway is modest: habitual coffee consumption does not need to be discouraged solely because of generalized metabolic concerns, but the Finnish findings remain observational and should not be translated into a prescription for increasing muscle mass or reducing visceral adiposity.